Ríos ZCA, Calderón PDE, Chávez MCA, Vega VO, Rosas CÓ

Language: Spanish
References: 23
Page: 266-272
PDF size: 191.26 Kb.

ABSTRACT

Introduction: End-stage renal disease is associated with malnutrition and increased morbidity, mortality, and hospitalization. Cachexia and sarcopenia are characterized by loss of muscle mass, but cachexia is accompanied with increased catabolism, inflammation, insulin resistance and anorexia. Due to the similarity of these conditions they are often misdiagnosed. Thus, we evaluated the frequency of cachexia and sarcopenia in end-stage renal disease on hemodialysis, the overlap of these identities and their association with quality of life. Objective: Evaluate the frequency, overlap and relationship with age of cachexia and sarcopenia in patients with end-stage renal disease on hemodialysis. As well as their association with other comorbidities and quality of life. Material and methods: Observational, multicentric study of 79 patients. We analyzed the frequency of cachexia and sarcopenia and did a simple logistic regression to look for risk factors associated with these pathologies. Variables with a statistically significant difference (p ‹ 0.01) were included in a multiple logistic regression analysis. Results: We found 18 patients (22.78%) had sarcopenia, 12 (15.18%) had cachexia and six (7.5%) had both. Age older than 60 years old associated with greater risk of cachexia and sarcopenia. Sarcopenia was associated with lower quality of life and diabetes mellitus. In the other hand, cachexia was associated with lower cognitive function, more depression, diabetes and physical quality of life. Conclusion: The principal’s risks factors associated with cachexia and sarcopenia were age older than 60 years, diabetes mellitus and poor quality of life in the physical sphere.

REFERENCES

1. Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int. 1999; 55 (4): 1560-1567.

2. Mafra D, Guebre-Egziabher F, Fouque D. Body mass index, muscle and fat in chronic kidney disease: questions about survival. Nephrol Dial Transplant. 2008; 23 (8): 2461-2466.

3. Thunberg BJ, Swamy AP, Cestero RV. Cross-sectional and longitudinal nutritional measurements in maintenance hemodialysis patients. Am J Clin Nutr. 1981; 34 (10): 2005-2012.

4. Finestone HM, Greene-Finestone LS, Wilson ES, Teasell RW. Prolonged length of stay and reduced functional improvement rate in malnourished stroke rehabilitation patients. Arch Phys Med Rehabil. 1996; 77 (4): 340-345.

5. Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr. 2007; 26 (4): 389-399.

6. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med. 2001; 137 (4): 231-243.

7. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39 (4): 412-423.

8. Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci. 2002; 57 (12): M772-M777.

9. Yoo SZ, No MH, Heo JW, Park DH, Kang JH, Kim SH et al. Role of exercise in age-related sarcopenia. J Exerc Rehabil. 2018; 14 (4): 551-558.

10. Chang YT, Wu HL, Guo HR, Cheng YY, Tseng CC, Wang MC et al. Handgrip strength is an independent predictor of renal outcomes in patients with chronic kidney diseases. Nephrol Dial Transplant. 2011; 26 (11): 3588-3595.

11. Springer J, von Haehling S, Anker SD. The need for a standardized definition for cachexia in chronic illness. Nat Clin Pract Endocrinol Metab. 2006; 2 (8): 416-417.

12. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D et al. Cachexia: a new definition. Clin Nutr. 2008; 27 (6): 793-799.

13. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006; 83 (4): 735-743.

14. Rolland Y, Abellan van Kan G, Gillette-Guyonnet S, Vellas B. Cachexia versus sarcopenia. Curr Opin Clin Nutr Metab Care. 2011; 14 (1): 15-21.

15. Mak RH, Cheung WW, Zhan JY, Shen Q, Foster BJ. Cachexia and protein-energy wasting in children with chronic kidney disease. Pediatr Nephrol. 2012; 27 (2): 173-181.

16. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008; 73 (4): 391-398.

17. Rosas-Carrasco O, González-Flores E, Brito-Carrera AM, Vázquez-Valdez OE, Peschard-Sáenz E, Gutiérrez-Robledo LM et al. Evaluación de la comorbilidad en el adulto mayor. Rev Med Inst Mex Seguro Soc. 2011; 49 (2): 153-162.

18. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012; 65 (9): 989-995.

19. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12 (3): 189-198.

20. Kim JK, Choi SR, Choi MJ, Kim SG, Lee YK, Noh JW et al. Prevalence of and factors associated with sarcopenia in elderly patients with end-stage renal disease. Clin Nutr. 2014; 33 (1): 64-68.

21. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56 (3): M146-M156.

22. Pumar MI, Gray CR, Walsh JR, Yang IA, Rolls TA, Ward DL. Anxiety and depression-Important psychological comorbidities of COPD. J Thorac Dis. 2014; 6 (11): 1615-1631.

23. Woo T, Yu S, Visvanathan R. Systematic literature review on the relationship between biomarkers of sarcopenia and quality of life in older people. J Frailty Aging. 2016; 5 (2): 88-99.